Prospective validation of patient fatigue questionnaire (FACIT‑F) for fatigue assessment in nab‑paclitaxel plus gemcitabine therapy

Okada,Ken‑Ichi; Hirono,Seiko; Kawai,Manabu; Miyazawa,Motoki; Shimizu,Atsushi; Kitahata,Yuji; Ueno,Masaki; Hayami,Shinya; Shimokawa,Toshio; Yamaue,Hiroki

doi:10.3892/mco.2017.1485

January-2018 Volume 8 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2018 Volume 8 Issue 1

Full Size Image

Article

Prospective validation of patient fatigue questionnaire (FACIT‑F) for fatigue assessment in nab‑paclitaxel plus gemcitabine therapy

Authors:
- Ken‑Ichi Okada
- Seiko Hirono
- Manabu Kawai
- Motoki Miyazawa
- Atsushi Shimizu
- Yuji Kitahata
- Masaki Ueno
- Shinya Hayami
- Toshio Shimokawa
- Hiroki Yamaue
View Affiliations / Copyright

Affiliations: Second Department of Surgery, Wakayama Medical University, Wakayama, Wakayama 641‑8510, Japan, Department of Clinical Study Support Center, Wakayama Medical University, Wakayama, Wakayama 641‑8510, Japan
Pages: 121-126
|
Published online on: November 3, 2017

https://doi.org/10.3892/mco.2017.1485
Expand metrics +

Abstract

Following the recent introduction of a stronger regimen for pancreatic carcinoma, patients undergoing chemotherapy present high incidences of fatigue. The feasibility and validity of evaluating fatigue by questionnaire for patients with unresectable pancreatic cancer (URPC) receiving this recent regimen of chemotherapy remains unclear. Enrolled patients completed the Functional Assessment of Cancer Therapy‑Fatigue questionnaire (FACIT‑F, version 4), a questionnaire regarding additional concerns, a numerical rating scale test concerning loss of appetite, an evaluation of degree of pain and sensory disorder, and the Patient Neurotoxicity Questionnaire (PNQ) before undergoing nab‑paclitaxel plus gemcitabine therapy. Questionnaires and tests were completed on registration day, and then weekly during therapy over an 8‑week period as the initial two cycles of continuous regimen. This trial is registered on the UMIN Clinical Trials Registry (UMIN000021758). Between April 2016 and September 2016, 10 consecutive patients with URPC, including metastatic (n=4) and locally advanced pancreatic (n=6) cancer, were registered, and scheduled for nab‑paclitaxel plus gemcitabine therapy. The mean maximum values of fatigue degree increased from mean baseline values in all categories of the questionnaire (6‑500%). The degree of fatigue presented a spike pattern over a 4‑week scheduled period as one cycle of regimen in time‑sequence diagram regarding 10/13 (77%) questionnaires. The PNQ concerning sensory/motor disorder also demonstrated a spike pattern and an increase from the baseline as the number of administrations. It is valid and feasible to assess fatigue by FACIT‑F questionnaire for patients with URPC undergoing nab‑paclitaxel plus gemcitabine therapy, and to detect detailed changes in accordance with scheduled cycles of chemotherapy regimen.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
3	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
4	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
5	Okada KI, Hirono S, Kawai M, Miyazawa M, Shimizu A, Kitahata Y, Ueno M, Hayami S and Yamaue H: Phase I study of nab-paclitaxel plus gemcitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Anticancer Res. 37:853–858. 2017. View Article : Google Scholar : PubMed/NCBI
6	Salsman JM, Beaumont JL, Wortman K, Yan Y, Friend J and Cella D: Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Support Care Cancer. 23:1355–1364. 2015. View Article : Google Scholar : PubMed/NCBI
7	Younossi ZM, Stepanova M, Charlton M, Curry MP, O'Leary JG, Brown RS and Hunt S: Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: An exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 1:122–132. 2016. View Article : Google Scholar : PubMed/NCBI
8	Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, et al: Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 17:1483–1491. 2009. View Article : Google Scholar : PubMed/NCBI
9	National Cancer Institute, . Common terminology criteria for adverse events (CTCAE) Version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdfMarch 3–2017
10	National Comprehensive Cancer Network, . NCCN practice guidelines for pancreatic cancer, version 2. 2016, http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdfOctober 4–2016
11	National Cancer Institute, . Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™). https://healthcaredelivery.cancer.gov/pro-ctcae/pro-ctcae_japanese.pdf#search=pro-ctcaeMarch 3–2017

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Prospective validation of patient fatigue questionnaire (FACIT‑F) for fatigue assessment in nab‑paclitaxel plus gemcitabine therapy

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles